慢性閉塞性肺疾患（COPD）治療薬の世界市場 - 2025年～2032年

世界の慢性閉塞性肺疾患（COPD）治療薬市場は、2024年に246億7,000万米ドルに達し、2032年には351億5,000万米ドルに達すると予測され、予測期間2025年～2032年にはCAGR 4.9％で成長する見込みです。

慢性閉塞性肺疾患（COPD）は、気道と肺組織の慢性炎症による持続的な呼吸器症状と気流制限を特徴とする進行性の呼吸器疾患です。この疾患は主に喫煙歴や有害汚染物質への曝露歴のある人に発症します。

COPDの主なタイプは慢性気管支炎で、このタイプは気道の長期にわたる炎症が特徴で、粘液分泌の増加と慢性的な咳を引き起こします。気道が狭くなるため、患者はしばしば呼吸困難を経験します。もう一つの肺気腫は、肺の肺胞（空気の袋）が損傷し、ガス交換の効率が低下します。この障害により息苦しさが生じ、体への酸素供給が減少します。

COPDの治療には、気管支拡張薬、コルチコステロイド、併用療法、新規治療などがあります。これらの要因が世界の慢性閉塞性肺疾患（COPD）治療薬市場拡大の原動力となっています。

市場力学：

促進要因と阻害要因

COPD有病率の増加

COPDの有病率の増加が世界の慢性閉塞性肺疾患（COPD）治療薬市場の成長を大きく牽引しており、市場予測期間中も牽引していくと予想されます。

慢性閉塞性肺疾患（COPD）は、気流の制限や呼吸困難を引き起こす肺の疾患です。肺気腫や慢性気管支炎と呼ばれることも多いです。COPDの主な原因は喫煙と大気汚染です。COPDの患者は、他の健康合併症を発症するリスクが高いです。

COPDは治る病気ではありませんが、喫煙を避け、大気汚染への暴露を制限すれば、症状はかなり改善します。予防接種も感染症の予防に役立ちます。治療の選択肢としては、薬物療法、酸素療法、肺機能と生活の質を高める肺リハビリテーションプログラムなどがあります。これらすべての要因が、世界の慢性閉塞性肺疾患（COPD）治療薬市場に需要をもたらしています。

慢性閉塞性肺疾患（COPD）の疫学

2024年11月の世界保健機関（WHO）のデータによると、慢性閉塞性肺疾患（COPD）は世界第4位の死因であり、2021年には350万人が死亡し、世界の全死亡者の約5％を占めています。特に、70歳未満のCOPD関連死の90％近くが中低所得国（LMICs）で発生しています。さらに、COPDは障害調整生存年数（DALYs）で測定すると、世界で8番目に健康状態を悪化させる原因となっています。

タバコ喫煙はCOPDの大きな原因であり、高所得国では症例の70％以上を占めています。一方、LMICsでは、タバコ喫煙はCOPD症例の30～40％を占め、家庭大気汚染が主要な危険因子として浮上しています。COPDの有病率の増加は、特にLMICsの脆弱な人々において、この重大な健康問題に対処するための効果的な公衆衛生戦略と介入が緊急に必要であることを浮き彫りにしています。

さらに、COPD治療薬市場の成長を後押しする製品の上市や承認も、業界の主要な企業によって進められています。例えば、2024年7月、欧州医薬品庁（EMA）はデュピクセント（デュピルマブ）を、血中好酸球の上昇を特徴とする制御不能な慢性閉塞性肺疾患（COPD）の成人患者に対する追加維持療法として承認しました。デュピクセントはCOPDの治療薬として初めて承認された標的治療薬であり、この慢性呼吸器疾患の治療における重要なニーズに応えるものです。これらすべての要因が、世界の慢性閉塞性肺疾患（COPD）治療薬市場の需要を促進しています。

さらに、併用療法へのシフトによる需要の高まりが、慢性閉塞性肺疾患（COPD）治療薬の世界市場拡大につながっています。

薬剤の副作用

COPD治療薬の世界市場では、薬剤の副作用が大きな抑制要因となっています。薬剤は慢性閉塞性肺疾患（COPD）を管理するために極めて重要であるが、関連する副作用は患者とヘルスケアプロバイダーの双方に様々な課題をもたらす可能性があります。

副作用の存在はCOPD患者のQOLに悪影響を及ぼしかねません。調査によると、治療に関連した副作用の強度が高いほど、健康関連QOL（HRQoL）の低下と相関することが示されています。例えば、錯乱、排尿困難、目のかすみなどの抗コリン性副作用は、COPD患者の大部分を占める高齢者にとって特に問題となります。システマティックレビューでは、ICSの使用が口腔カンジダ症や発声障害などの局所障害と関連し、HRQoLをさらに低下させることが強調されています。

副作用は処方された治療レジメンに対する患者のアドヒアランスに大きな影響を与えます。COPD患者の多くは、抗コリン薬による口渇や喉の炎症などの副作用を経験する可能性があります。長時間作用型β作動薬（LABA）による心拍数の増加、振戦、めまいです。ロフルミラストによる体重減少、吐き気、下痢、不眠。これらの副作用は、患者の服薬継続意欲を減退させ、疾患管理の不良や増悪リスクの増大につながります。例えば、COPD患者における吸入コルチコステロイド（ICS）の長期使用は、非使用者と比較して肺炎のリスクが41％増加することが研究で明らかになっており、これはアドヒアランスを著しく阻害します。このように、上記の要因が世界の慢性閉塞性肺疾患（COPD）治療薬市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • COPDの罹患率の増加
  • 抑制要因
    • 薬の副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 薬剤クラス別

• 気管支拡張薬
  • 抗コリン吸入薬
  • アクリジニウム
  • グリコピロニウム
  • チオトロピウム
  • ウメクリジニウム
  • レベフェナシン
  • その他
  • ベータ作動薬吸入器
  • アルフォルモテロール
  • サルメテロール
  • オロダテロール
  • その他
  • 吸入コルチコステロイド
• ベクロメタゾン
  • シクレソニド
  • モメタゾン
  • ブデソニド
  • その他
• 複合吸入薬
  • アルブテロールとイプラトロピウム
  • ブデソニドとフォルモテロール
  • フルチカゾンとサルメテロール
  • フルチカゾンとビランテロール
  • フォルモテロールとモメタゾン
  • その他
• ホスホジエステラーゼ阻害剤（ロフルミラスト）
• 抗生物質（アジスロマイシン）
• その他

第7章 投与経路別

• 吸入
• 経口
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Boehringer Ingelheim Pharmaceuticals, Inc.
  • 会社概要
  • 製品ポートフォリオと概要
  • 財務概要
  • 主な発展
• Gsk Plc
• Viatris Inc.（Mylan N.V.）
• Lupin Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• AstraZeneca
• Organon Group of companies
• Pfizer Inc.
• Covis Pharma GmbH

第12章 付録

The global chronic obstructive pulmonary disease (COPD) drugs market reached US$ 24.67 billion in 2024 and is expected to reach US$ 35.15 billion by 2032, growing at a CAGR of 4.9% during the forecast period 2025-2032.

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory condition characterized by persistent respiratory symptoms and airflow limitation caused by chronic inflammation of the airways and lung tissue. The disease primarily affects individuals with a history of smoking or exposure to harmful pollutants.

The main type of COPD is chronic bronchitis this type is marked by long-term inflammation of the airways, leading to increased mucus production and a chronic cough. Patients often experience difficulty breathing due to narrowed airways. Another one is emphysema involves damage to the alveoli (air sacs) in the lungs, resulting in reduced efficiency in gas exchange. This damage leads to breathlessness and decreased oxygen supply to the body.

Treatment for COPD includes bronchodilators, corticosteroids, combination therapies, and novel therapies. These factors have driven the global chronic obstructive pulmonary disease (COPD) drugs market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of COPD

The increasing prevalence of COPD is significantly driving the growth of the global chronic obstructive pulmonary disease (COPD) drugs market and is expected to drive throughout the market forecast period.

Chronic obstructive pulmonary disease (COPD) is a prevalent lung condition that leads to restricted airflow and breathing difficulties. It is often referred to as emphysema or chronic bronchitis. The primary causes of COPD are smoking and air pollution. Individuals with COPD face a higher risk of developing other health complications.

While COPD is not curable, symptoms can improve significantly if individuals avoid smoking and limit exposure to air pollution. Vaccinations can also help prevent infections. Treatment options include medications, oxygen therapy, and pulmonary rehabilitation programs to enhance lung function and quality of life. All these factors demand the global chronic obstructive pulmonary disease (COPD) drugs market.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology

According to the World Health Organization (WHO) data in November 2024, chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death globally, resulting in 3.5 million deaths in 2021, which accounts for approximately 5% of all deaths worldwide. Notably, nearly 90% of COPD-related deaths among individuals under the age of 70 occur in low- and middle-income countries (LMICs). Furthermore, COPD ranks as the eighth leading cause of poor health worldwide when measured by disability-adjusted life years (DALYs).

Tobacco smoking is a significant contributor to COPD, accounting for over 70% of cases in high-income countries. In contrast, in LMICs, tobacco smoking is responsible for 30-40% of COPD cases, with household air pollution emerging as a major risk factor. The increasing prevalence of COPD highlights the urgent need for effective public health strategies and interventions to address this critical health issue, particularly in vulnerable populations in LMICs.

Furthermore, key players in the industry product launches and approvals that would drive this COPD drugs market growth. For instance, in July 2024, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by elevated blood eosinophils. This marks a significant milestone as Dupixent becomes the first targeted therapy approved for COPD, addressing a critical need in the management of this chronic respiratory condition. All these factors demand the global chronic obstructive pulmonary disease (COPD) drugs market.

Moreover, the rising demand for the growth of shift towards combination therapies to the global chronic obstructive pulmonary disease (COPD) drugs market expansion.

Adverse Effects of Drugs

The adverse effects of drugs present a significant restraint in the global COPD drugs market. While medications are crucial for managing chronic obstructive pulmonary disease (COPD), the associated side effects can lead to various challenges for both patients and healthcare providers.

The presence of adverse effects can negatively influence the quality of life for COPD patients. Research indicates that higher intensity of treatment-related adverse effects correlates with a decline in health-related quality of life (HRQoL). For instance, anticholinergic side effects such as confusion, urinary hesitation, and blurred vision are particularly concerning for older adults, who constitute a significant portion of the COPD population. A systematic review highlighted that ICS use is linked to local disorders like oral candidiasis and dysphonia, which further diminish HRQoL.

Adverse effects can significantly affect patient adherence to prescribed treatment regimens. Many COPD patients may experience side effects such as dry mouth and throat irritation from anticholinergic medications. Increased heart rate, tremors, and dizziness from long-acting beta-agonists (LABAs).Weight loss, nausea, diarrhea, and insomnia from roflumilast. These side effects can discourage patients from continuing their medication, leading to poor disease management and increased risk of exacerbations. For example, a study found that long-term use of inhaled corticosteroids (ICS) in COPD patients is associated with a 41% increased risk of pneumonia compared to non-users, which can significantly deter adherence. Thus, the above factors could be limiting the global chronic obstructive pulmonary disease (COPD) drugs market's potential growth.

Segment Analysis

The global chronic obstructive pulmonary disease (COPD) drugs market is segmented based on drug class, route of administration, distribution channel, and region.

Drug Class:

The bronchodilators segment is expected to dominate the global chronic obstructive pulmonary disease (COPD) drugs market share

The bronchodilators segment holds a major portion of the global chronic obstructive pulmonary disease (COPD) drugs market share and is expected to continue to hold a significant portion of the global chronic obstructive pulmonary disease (COPD) drugs market share during the forecast period.

The bronchodilators segment is a vital part of the global COPD drugs market, primarily due to its effectiveness in alleviating the symptoms of chronic obstructive pulmonary disease (COPD). Bronchodilators are medications that relax and widen the airways, enhancing airflow and making it easier for patients to breathe. Below is a comprehensive overview of this segment:

Types of bronchodilators include beta-adrenergic agonists, SABAs, albuterol (ProAir, Ventolin), LABAs, salmeterol (Serevent), formoterol (Foradil) anticholinergics, combination bronchodilators and others. These products combine different classes of bronchodilators or include corticosteroids to enhance efficacy and provide comprehensive symptom management.

The increasing prevalence of respiratory conditions such as COPD is a primary driver for the bronchodilator segment. Factors such as smoking, air pollution, and an aging population contribute to higher rates of COPD, thereby increasing demand for bronchodilator therapies.

Furthermore, key players in the industry product launches and approvals that would drive this segment growth in the COPD drugs market. For instance, in June 2024, Verona Pharma plc announced that the U.S. Food and Drug Administration (FDA) has approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. This approval is particularly notable as Ohtuvayre is the first inhaled product with a novel mechanism of action to be introduced for the maintenance treatment of COPD in over 20 years.

Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4). This innovative medication combines both bronchodilator and non-steroidal anti-inflammatory effects within a single molecule. It is administered directly to the lungs using a standard jet nebulizer, eliminating the need for high inspiratory flow rates or complex hand-breath coordination. These factors have solidified the segment's position in the global chronic obstructive pulmonary disease (COPD) drugs market.

Geographical Analysis

North America is expected to hold a significant position in the global chronic obstructive pulmonary disease (COPD) drugs market share

North America holds a substantial position in the global chronic obstructive pulmonary disease (COPD) drugs market and is expected to hold most of the market share.

The increasing incidence of chronic obstructive pulmonary disease (COPD) in North America is a major driver for the COPD drugs market. In the United States alone, approximately 16 million adults are diagnosed with COPD, and many more remain undiagnosed. This high prevalence necessitates effective treatment options, fuelling demand for COPD medications. COPD is also a leading cause of death and disability in the region, further emphasizing the need for robust treatment solutions.

Approximately half of patients with chronic obstructive pulmonary disease (COPD) continue to experience exacerbations even while on triple inhaled therapy. In the United States, around 300,000 individuals live with inadequately controlled COPD and exhibit an eosinophilic phenotype. Patients with this phenotype face an estimated 30% increase in exacerbations and a heightened risk of COPD-related hospitalizations within a year.

The aging demographic in North America significantly contributes to the rise in COPD cases. As individuals age, they become more susceptible to respiratory diseases due to cumulative exposure to risk factors such as smoking and environmental pollutants. The growing elderly population is expected to increase the demand for therapies aimed at managing COPD effectively.

Continuous research and development efforts focused on creating innovative therapies for COPD are driving market growth. The introduction of new drug formulations, including combination therapies and biologics, enhances treatment efficacy and patient adherence. For example, advancements in inhalation technologies, such as soft mist inhalers and breath-activated devices, improve drug delivery and compliance among patients.

Furthermore, a major number of key players are present, with well-advanced healthcare infrastructure, and drug launches and approvals that would drive this COPD drugs market growth. For instance, in September 2024, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) who have an eosinophilic phenotype. This makes Dupixent the first biologic medication approved in the United States specifically for this patient population.

Thus, the above factors are consolidating the region's position as a dominant force in the global chronic obstructive pulmonary disease (COPD) drugs market.

Asia Pacific is growing at the fastest pace in the global chronic obstructive pulmonary disease (COPD) drugs market share

Asia Pacific holds the fastest pace in the global chronic obstructive pulmonary disease (COPD) drugs market and is expected to hold most of the market share.

The rising incidence of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region is a significant driver of market growth. High smoking rates, urbanization, and exposure to air pollution contribute to the increasing prevalence of respiratory diseases. For instance, it is estimated that millions are affected by COPD in countries like China and India, leading to heightened demand for effective treatment options. According to the World Health Organization (WHO), more than 90% of deaths from COPD occur in low- and middle-income countries, underscoring the urgent need for improved healthcare solutions in the region.

The demographic shift towards an aging population in the Asia-Pacific region significantly impacts the COPD market. Older adults are more susceptible to respiratory diseases due to cumulative exposure to risk factors over their lifetime. As the population ages, the demand for COPD management therapies is expected to rise, further driving market growth. The proportion of individuals aged 60 and older is projected to increase significantly, creating a larger patient base for COPD treatments.

Continuous research and development efforts aimed at creating innovative therapies for COPD are propelling market growth. The introduction of new drug formulations, including combination therapies and biologics, enhances treatment efficacy and patient adherence. For example, advancements in inhalation technologies, such as soft mist inhalers and breath-activated devices, improve drug delivery and compliance among patients. The commitment to developing targeted treatments tailored to regional healthcare challenges is also a key factor.

Furthermore, key players in the industry have innovative launches that would drive this COPD drug market growth. For instance, in November 2023, Lupin Limited recently made a significant advancement in the treatment of chronic obstructive pulmonary disease (COPD) by launching Vilfuro-G, the world's first fixed-dose triple combination drug (FDC) designed specifically for this condition. This innovative medication combines three active ingredients: Vilanterol, Fluticasone Furoate, and Glycopyrronium Bromide. It is intended for the long-term management of moderate to severe COPD, which affects over 37 million individuals in India alone and is a leading cause of death and disability in the country.

Thus, the above factors are consolidating the region's position as the fastest-growing force in the global chronic obstructive pulmonary disease (COPD) drugs market.

Competitive Landscape

The major global players in the chronic obstructive pulmonary disease (COPD) drugs market include Boehringer Ingelheim Pharmaceuticals, Inc., GSK plc, Viatris Inc. (Mylan N.V.), Lupin Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca, Organon group of companies, Pfizer Inc., and Covis Pharma GmbH among others.

Key Developments

• In September 2024, GSK announced positive results from the MATINEE Phase III clinical trial evaluating Nucala (mepolizumab) for the treatment of chronic obstructive pulmonary disease (COPD). This trial is significant as it demonstrates the potential of Nucala, a monoclonal antibody that targets interleukin-5 (IL-5), to reduce exacerbations in COPD patients.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global chronic obstructive pulmonary disease (COPD) drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of COPD
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects of Drugs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 6.1.2. Market Attractiveness Index, By Drug Class
• 6.2. Bronchodilators*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Anticholinergic Inhalers
  • 6.2.4. Aclidinium
  • 6.2.5. Glycopyrronium
  • 6.2.6. Tiotropium
  • 6.2.7. Umeclidinium
  • 6.2.8. Revefenacin
  • 6.2.9. Others
  • 6.2.10. Beta-Agonist Inhalers
  • 6.2.11. Arformoterol
  • 6.2.12. Salmeterol
  • 6.2.13. Olodaterol
  • 6.2.14. Others
  • 6.2.15. Inhaled Corticosteroids
• 6.3. Beclomethasone
  • 6.3.1. Ciclesonide
  • 6.3.2. Mometasone
  • 6.3.3. Budesonide
  • 6.3.4. Others
• 6.4. Combination Inhaled Medicines
  • 6.4.1. Albuterol and Ipratropium
  • 6.4.2. Budesonide and formoterol
  • 6.4.3. Fluticasone and salmeterol
  • 6.4.4. Fluticasone and vilanterol
  • 6.4.5. Formoterol and mometasone
  • 6.4.6. Others
• 6.5. Phosphodiesterase Inhibitor (Roflumilast)
• 6.6. Antibiotics (Azithromycin)
• 6.7. Others

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Inhalation*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Oral
• 7.4. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Hospital Pharmacies
• 8.4. Retail Pharmacies
• 8.5. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Boehringer Ingelheim Pharmaceuticals, Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Gsk Plc
• 11.3. Viatris Inc. (Mylan N.V.)
• 11.4. Lupin Pharmaceuticals, Inc.
• 11.5. Teva Pharmaceutical Industries Ltd.
• 11.6. AstraZeneca
• 11.7. Organon Group of companies
• 11.8. Pfizer Inc.
• 11.9. Covis Pharma GmbH

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us